Actively Recruiting
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Led by Innovent Biologics (Suzhou) Co. Ltd. · Updated on 2024-12-19
178
Participants Needed
9
Research Sites
142 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
CONDITIONS
Official Title
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and provide written informed consent
- Male or female aged 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected life expectancy of at least 3 months
You will not qualify if you...
- Inadequate bone marrow or organ function
- Received chemotherapy or targeted small molecule therapy within 2 weeks or 5 plasma half-lives
- Received Nitrosoureas or mitomycin C within 6 weeks prior to study drug start and during study
- Received anti-cancer monoclonal antibody within 4 weeks prior to study drug start
- Received live vaccines within 28 days prior to the study drug or plan to receive live vaccines during the study
- Have unresolved adverse reactions from previous antitumor treatments above Grade 1 toxicity (except alopecia, fatigue, pigmentation, or other conditions deemed safe by investigator)
- Underwent major surgery (craniotomy, thoracotomy, laparotomy, or other significant surgery) within 4 weeks prior to study drug start
- Expected to have major surgery during the study period
- Have severe unhealed wounds, trauma, or ulcers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
University of California, San Francisco (UCSF)
San Francisco, California, United States, 94143
Actively Recruiting
2
Ocala Oncology Center
Ocala, Florida, United States, 34474
Actively Recruiting
3
BRCR Medical Center
Plantation, Florida, United States, 33322
Actively Recruiting
4
University of Kansas Medical Center (KUMC)
Fairway, Kansas, United States, 66205
Actively Recruiting
5
Michigan Hematology & Oncology Consultants - MedOnc Dearborn
Dearborn, Michigan, United States, 48126
Actively Recruiting
6
Michigan Hematology & Oncology Consultants - MedOnc Troy
Troy, Michigan, United States, 48098
Actively Recruiting
7
MD Anderson Cancer Center-University of Texas
Houston, Texas, United States, 77025
Actively Recruiting
8
Oncology Consultants P.A.
Houston, Texas, United States, 77030
Actively Recruiting
9
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
A
Amanda Guo
CONTACT
W
William Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here